C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home › Markets › Loading…
VRNOF Equity

VRNOF

OTCMKTS · VRNOF

$1.32
—
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 2/5
54/100 composite
Fundamentals70
Regulatory58
Market40
Editorial30
Composite · trailing 12 months

Verano Holdings earns a Neutral rating at a 53.5 composite score, with conviction at two out of five. The 70-point fundamentals pillar provides the principal support, driven by strong gross-margin and operating-margin subscores, positive EBITDA, and a favorable cash-runway subscore despite a stretched financial condition. Regulatory contributes a more moderate 58 points, reflecting a supportive jurisdiction and no enforcement hits, offset by weak filing cadence. Market and editorial pillars constrain the rating at 40 and 30, respectively: institutional pricing feeds provide no available quote, while CIN newsroom coverage contains no recent newsroom or brief activity.

Licensed fundamentals data show year-over-year revenue contracting by roughly 6.4%, making top-line momentum the central weakness within the strongest pillar. That decline contrasts with a gross margin slightly above 50% and an operating margin of approximately 7.2%, both of which indicate meaningful underlying profitability at the operating level. EBITDA stands near $210 million, but net income remains deeply negative at roughly $347 million, preserving the stretched financial assessment and preventing operating profitability from translating into a stronger rating. Primary regulatory filings show no reportable events over either the latest 90-day or 180-day periods and no enforcement hits. However, no latest filing date is available, consistent with the low cadence subscore and limiting the regulatory pillar’s contribution.

The clearest re-rating catalyst sits inside fundamentals, where margin strength already establishes an operating base for improved earnings quality. A recovery in sales momentum could convert the current gross-margin and operating-margin profile into stronger operating leverage, while continued contraction would leave the positive EBITDA signal overshadowed by the substantial net loss. Regulatory stability offers secondary support through the strong jurisdiction and enforcement subscores, but absent filing recency, that pillar lacks enough momentum to lead a rating change. Market confirmation also remains unavailable through institutional pricing feeds, and editorial visibility remains limited in CIN newsroom coverage. The single most important forward-looking signal is a return to positive year-over-year revenue growth.

Scored: 2026-10-14Valid through: 2026-11-28Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
IR & AgencyInvestor relations
Corporate DetailsCompany profile
CEO
George Archos
CFO
Rich Tarapchak
SEC CIK
0001848416
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$426.9M
Enterprise value
$904.6M
Price to book
0.54
Price to sales
0.41
EV / EBITDA
6.44
Revenue (TTM)
$833.1M
Gross profit (TTM)
$419.2M
EBITDA
$210.3M
Operating margin
7.2%
Profit margin
-41.7%
Rev growth YoY
-6.4%
Return on equity
-33.0%
Return on assets
2.5%
EPS (TTM)
$-0.99
EPS est. current year
$-0.26
Wall St. target price
$5.00
Shares outstanding
361.8M
Insider ownership
13.4%
Institutional ownership
10.2%
Beta
1.67
Full-time employees
3,800
GICS sector
Healthcare
GICS industry
Drug Manufacturers - Specialty & Generic
Filings & DisclosuresPrimary sources
Filing portal
SEDAR+
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for VRNOF (VRNOF)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for VRNOF (VRNOF), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)

Bullish and bearish analyst opinions for Verano Holdings (VRNOF)

Bullish view. Verano Holdings is a top-tier US MSO with market-leading positions in Florida, New Jersey, and Illinois, plus a maturing Ohio adult-use footprint; bulls model operating-margin expansion as flagship states scale and note the brand portfolio (Zen Leaf retail, Encore concentrates, MUV medical) drives premium price capture that peers struggle to match.

Bearish view. Bearish views cite Florida adult-use referendum uncertainty, 280E cash-tax drag that limits reinvestment capacity, and MSO multiple compression that has held the whole peer group at deep discounts to consumer-staples benchmarks.

Live ratings, price targets, and consensus figures for Verano Holdings appear above this summary. Explore analyst coverage across the 326-equity cannabis universe.

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for VRNOF are maintained by Cannabis Investor News and refreshed throughout the trading day.